Tjoapack is a GMP/FDA certified contract packaging organisation with production facilities in both Europe and US. Our packaging capabilities covers a full range of standard services such as primary packaging of oral solids including commercial blistering, bottles, unit dose for hospitals and secondary packaging of all forms, also kitting and clinical trials. We also provide customised and effective solutions for commercial packaging of vials and pre-filled syringes.

  • NL
  • 2017
    On CPHI since
  • 2
  • 250 - 499
Company types
Contract Service
Distributor/Import Export
Contact info
Meet us at

CPHI Frankfurt 2022

Messe Frankfurt, Germany
1-3 November 2022


  • Packaging and Supply Chain Solutions

    Product Packaging and Supply Chain Solutions

    Tjoapack's packaging and supply chain solutions help our customers to make the world a healthier place. Our expert team work to facilitate your life sciences research, production and the delivery of medicines to patients across the globe.
    We offer: - Packaging solutions for; oral solid blisters and ...


  • News Tjoapack invests over €10m into Etten-Leur facility

    Global contract packaging organisation (CPO), Tjoapack, has announced a €10m+ investment into its packaging and supply chain facility in Etten-Leur, Netherlands over the next two years.
  • Brochure Tjoapack invests over €10m into Etten-Leur facility

    At Tjoapack we're dedicated to shaping the future of the pharmaceutical supply chain which is why we're delighted to announce that over the next two years we'll be expanding our facility in Etten-Leur from 8,400sq.m. to 11,500 sq.m.

    The investment of over €10m will more than double our primary packaging capacity for oral solids, as well as bolster our warehousing and cold chain capabilities to meet demand for our value-added logistics services.

    Read more here
  • Whitepaper Postponement packaging whitepaper

    Postponement packaging is the practice of keeping products in a semi-finished, market agnostic state, and only finalising them when there is a specific market demand.

    Used strategically, it will allow pharmaceutical manufacturers to respond to market-related fluctuation as well as variations in packaging requirements. In addition, postponement will enable pharma companies to lower working capital by reducing finished goods inventories, avoid repackaging work, reduce waste across the supply chain, and shorten their return on investment cycle.

    In this whitepaper, Dr Anita Paz, Innovation Consultant and Dexter Tjoa, CEO (formerly Director Corporate Strategy) at Tjoapack, outline the postponement packaging principle and the key points to consider before implementing it as a supply chain strategy. They also discuss how this approach can be applied to different product portfolios and the benefits that adoption could bring to the pharmaceutical industry.

    For more information on postponement packaging visit